Aydah AlAwadhi, MD 🇦🇪· @Aydah_AlAwadhi · X·· 12 hours agoScore70
Body
Well-deserved standing ovation! The Phase 3 DeLLphi-305 trial showed that adding tarlatamab-dlle to durvalumab maintenance therapy significantly improved OS in lung cancer (ES-SCLC) patients without progression after initial chemoimmunotherapy. @myESMO @OncoAlert #bcsm #ESMO26
122 views · 1 like · 1 repost · 0 replies
Conference abstracts
LBA3matched by Presidential Symposium I
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgSource: Aydah AlAwadhi, MD 🇦🇪 · x.com